d13

D13 is an acylhydrazone antifungal.1 It is active against C. neoformans in vitro (MIC80 = 0.06 μg/ml). D13 (20 mg/kg per day, p.o.) increases survival in mouse models of C. neoformans, C. albicans, or A. fumigatus infection. |1. Lazzarini, C., Haranahalli, K., Rieger, R., et al. Acylhydrazones as antifungal agents targeting the synthesis of fungal sphingolipids. Antimicrob. Agents Chemother. 62(5), e00156-00118 (2018).

Colfosceril miristate-d13 (DMPC-d13) is the deuterated form of Colfosceril miristate. Colfosceril miristate (DMPC) is a synthetic phospholipid utilized in the study of liposomes and lipid bilayers. It is employed for research on lipid monolayers and bilayers.

Lusutrombopag-d13 is a deuterated compound of Lusutrombopag. Lusutrombopag has a CAS number of 1110766-97-6. Lusutrombopag is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery.

Alachlo-d13 (2,6-diethylphenyl-d13) is a deuterated compound of Alachlo.

TD139 is a small molecule inhibitor of inhaled galectin-3 (Gal-3) with potential anti-fibrotic activity, commonly used in the study of idiopathic pulmonary fibrosis.

MD13 is a macrophage migration inhibitor (MIF) oriented PROTAC (Ki value: 71 nM). MD13 can be used to study cancer.

The KD values of D13-9001 in Escherichia coli and Pseudomonas aeruginosa were 1.15μM and 3.57μM, respectively. D13-9001 has antibiotic activity. It is an effective AcrB (AcrAB-TolC efflux pump subunit) and MexB (MexAB-OprM efflux pump subunit) inhibitor.

Choline-d13 Bromide (N,N,N-trimethyl-d9; 1,1,2,2-d4) is a deuterated compound of Choline Bromide. Choline Bromide has a CAS number of 1927-06-6.

CD13-IN-1 (Compound 5f) is a CD13 inhibitor with an IC50 value of 1.71 μM. It effectively suppresses the proliferation of various tumor cells, demonstrating antitumor activity.

SD133 (Sd-133) is a cadherin-11 inhibitor for studying tumors overexpressing cadherin-11.

AZD1390 is an exceptionally potent inhibitor of ATM in cells (IC50: 0.78 nM) with >10,000-fold selectivity over closely related members of the PIKK family of enzymes.

ZDLD13 is a β-carboline that exhibits potent anti-HCT116 activity inclusive of inhibition of invasion and migration, inhibition of colony formation, inducing of apoptosis as well as arresting of G1 phase in cell cycle. ZDLD13 is an orally active and selective inhibitor of CDK4/CycD3 (IC 50 = 0.38 μM) which exhibits significant inhibition of tumor growth in HCT116 tumor xenograft model [1].

NVP-BBD130 is a stable, ATP-competitive, potent, orally active inhibitor of PI3K and mTOR.

AZD1386 is a TRPV1 antagonist. AZD1386 acts as a competitive antagonist at the channel's capsaicin binding site.

MIF degrader MD13 is involved in protein-protein interactions that play key roles in inflammation and cancer. Current strategies to develop small molecule modulators of MIF functions are mainly restricted to the MIF tautomerase active siteMIF degrader MD13. MD13 also exhibits antiproliferative effect in a 3D tumor spheroid model. In conclusion, we describe the first MIF-directed PROTAC (MD13) as a research tool, which also demonstrates the potential of PROTACs in cancer therapy.

Aminopeptidase N Ligand (CD13) NGR peptide, a polypeptide that targets CD13, functions as a carrier for mediating intracellular transmission and is commonly utilized in cancer research [1][2].

HDAC/CD13-IN-1 (Compound 12) is an inhibitor of both HDAC and CD13, with IC50 values of 0.34 μM for hCD13, 0.53 μM for porcine CD13, and 0.03, 0.06, and 0.02 μM for HDAC1, HDAC2, and HDAC3, respectively. This compound effectively suppresses proliferation and induces apoptosis in MV4-11, K562, Jeko-1, and HL60 cancer cells, with IC50 ranges of 0.25-2.04 μM, and demonstrates capabilities in hindering metastasis and invasion [1].

Anti-MouseOX40/CD134(LALA-PG) Antibody (OX86) is an IgG2a, κ inhibitor antibody derived from mice, targeting the mouse OX40/CD134 protein.

Anti-Mouse 4-1BBL/CD137L (D265A) Antibody (TKS-1) is an IgG1, κ inhibitory antibody derived from mice, specifically targeting mouse 4-1BBL/CD137L.

Anti-Mouse 4-1BBL/CD137L Antibody (TKS-1-MouseIgG2a) is an IgG2a, κ inhibitor antibody derived from mice, targeting mouse 4-1BBL/CD137L.

Anti-Mouse 4-1BB/CD137 (LALA-PG) Antibody (LOB12.3) is an IgG2a, κ agonistic antibody derived from mice, specifically targeting mouse 4-1BB/CD137.

Anti-Mouse 4-1BBL/CD137L (LALA-PG) Antibody (TKS-1) is an IgG2a, κ antibody inhibitor derived from mice that targets mouse 4-1BBL/CD137L.

Anti-Mouse CD132 (common γ chain) Antibody (3E12) is a rat-derived IgG2b antibody inhibitor targeting mouse CD132.

The Anti-Mouse OX40L/CD134L Antibody (RM134L) is an IgG2b, κ antibody inhibitor derived from rats, targeting mouse OX40L/CD134L.